Pathway
Bempedoic acid therapy in atherosclerosis and metabolic syndrome
"Mechanisms of action of bempedoic acid. In the cytoplasm of hepatocytes, ACSVL1 converts bempedoic acid to bempedoyl-CoA that directly inhibits ACLY. This is a key enzyme responsible for generatin...
WP:5500
What the reference databases state
Statements
26 statements
26 statements · 1 reference database · Subject: Bempedoic acid therapy in atherosclerosis and metabolic syndrome · Sources: WikiPathways
- ACACA participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- ACACB participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- ACLY participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- CRP participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- G6PC1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- G6PC2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- G6PC3 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- HMGA1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK10 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK11 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK12 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
Show the remaining 14
- MAPK13 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK14 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK3 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK8 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- MAPK9 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PCK2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAA1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAA2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAB1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAB2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAG1 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAG2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- PRKAG3 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only
- SLC27A2 participates in Bempedoic acid therapy in atherosclerosis and metabolic syndromeProteinWikiPathways WP5500Inferred only